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An 8-year-old, male neutered English Cocker Spanielpresented to the Royal Veterinary College for eval-
uation of reluctance to exercise and spinal hyperesthesia
of 1-year duration. Medical treatment by referring vet-
erinarian with antibiotics and tramadol did not result in
clinical improvement. Survey radiographs performed
before referral revealed multiple lytic bone lesions
involving sternum and ribs. The dog had been fed for
several months on a hypoallergenic diet and adminis-
tered prednisolone for presumed inflammatory bowel
disease.
General physical examination did not reveal abnor-
malities. Neurological examination revealed a kyphotic
posture and a short and stilted pelvic limb gait. Spinal
hyperesthesia could be elicited on thoracic, thoracolum-
bar, and lumbar spinal palpation. A complete blood
count and free catch urine analysis did not reveal
abnormalities. Serum biochemistry profile revealed
hypoalbuminemia (20.3 g/L [RI (reference interval) 28–
39 g/L]) and increased inorganic phosphorus concentra-
tion (2.68 mmol/L [RI 0.8–2 mmol/L]), alanine amino-
transferase activity (234 U/L [RI 13–88 U/L]) and
alkaline phosphatase activity (1425 U/L [RI 19–285 U/
L]). Ionized calcium concentration was within the RI.
Magnetic resonance imaging (MRI) imaging was per-
formed using a protocol that included sagittal and
transverse plane T2-weighteda (repetition time, TR [ms],
echo time, TE [ms], 3000/120) (Fig 1A), sagittal T2-
weighted short-tau inversion recovery (TR/TE, 3612/80)
(Fig 1C) and sagittal and transverse plane T1-weighted
spectral presaturation with inversion recovery (TR/TE,
533/8) sequences. Sagittal and transverse plane T1-
weighted (T1W turbo spin echo) (TR/TE, 400/8) images
were acquired before and after IV injection with
gadolinium contrastb (Fig 1B, D). Magnetic resonance
imaging demonstrated multiple poorly defined, expan-
sile lytic lesions affecting the spinous processes of the
sacrum, L5, L3, T13, T12, T11, T8, and T2, the verte-
bral bodies of the sacrum, L5, L4, T13, T12, T11, T9,
T7, T6, and T2, and multiple sternebrae. These lesions
were characterized by a heterogeneous intensity in all
sequences and patchy contrast enhancement. A fracture
of the vertebral body of T11 with bone remodeling was
present without spinal cord compression. After MRI,
thorax and abdomen computed tomography (CT) was
performed using a 16-slice scanner.c CT imaging
(Fig 2A) confirmed the expansile lytic bone lesions and
revealed additional lesions affecting multiple ribs and
pelvis and accounting for more than 20 bone lytic
lesions with variable sizes. CT did not reveal any abnor-
malities involving thoracic or abdominal visceral struc-
tures and no enhancement was seen after IV
administration of contrast medium.d Based on imaging
and laboratory results, nonproductive multiple myeloma
was considered the most likely differential diagnosis.
The lack of a clear primary lesion, the numerous bones
involved and absence of visceral lesions was not typical
for axial osteosarcoma (OS), even considering concur-
rent multiple metastases. The imaging findings were
more suggestive of synchronous multicentric osteosar-
coma (MOS), a rare OS clinical presentation in people,
with simultaneous multiple bone lesions without pul-
monary involvement1 and extremely rare in domestic
animals, which was considered as a rare differential
diagnosis.
Bone marrow aspirate (left humerus) and serum elec-
trophoresis did not reveal abnormalities and evaluation
of urine for Bence-Jones proteins was negative. Ultra-
sound guided fine needle aspirates of affected lesions
(dorsal spinous process of L5 and rib) were inconclu-
sive. Subsequently, the dog was anesthetized and a
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surgical biopsy of the spinous process of L5 was
obtained via a standardized dorsal approach. Bacterial
and fungal cultures obtained during surgery were
negative. The dog was discharged with pain relief con-
sisting of paracetamol/codeine (8 and 0.7 mg/kg, respec-
tively, PO q12 h), buprenorphine 20 lg/kg PO q8-12 h,
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Fig 1. Sagittal magnetic resonance imaging (MRI) shows multiple heterogeneous lesions within the vertebral column and the sternebrae,
A (T2-weighted), C (T2-weighted short-tau inversion recovery), white arrows indicate examples of these lesions. Transverse T1-weighted
pre- (B) and postcontrast (D) MRI illustrates a lesion of T11. The level of T12 is indicated as a white arrowhead in A.
A
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Fig 2. A full body computed tomography at the time of diagnosis (A) and 14 months later (B) shows multiple and progressive osteolytic
lesions of the vertebral column, sternum and pelvis. The black arrowhead indicates a pathological fracture at the level of T11.
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and also prednisolone 0.8 mg/kg PO q12 h.
Histopathology of the removed spinous process revealed
foci of osteolysis characterized by infiltration and
replacement of pre-existing bone by plump polygonal to
spindle-shaped cells. These infiltrating cells displayed
mild-moderate nuclear atypia with scattered mitoses
(average <1 per 10 hpf). The neoplastic cells produced
extensive poorly mineralized osteoid (Fig 3A). Neoplas-
tic cells displayed immunoreactivity for Vimentin and
Osteocalcin antigens (Fig 3B) and no immunoreactivity
for MUM-1 and CD79a antigens. Histopathological
and immunohistochemical results were compatible with
OS making a clinical diagnosis of MOS most likely.
Initial treatment after diagnosis focused on pain con-
trol as this was the main clinical sign and cause of deteri-
oration. It consisted of transition from prednisolone to
firocoxib (5 mg/kg PO, q24 h), and from buprenorphine
to tramadol (3–4 mg/kg PO, q8–q12 h), continuation of
paracetamol/codeine and start of pamidronate (1 mg/kg
in 0.9% NaCl IV, every 3–4 weeks). Hypofractionated
radiation treatment was administered to selected lytic
lesions, resulting in a higher degree of pain control based
on physical and neurological examinations, with a total
of 4 fractions of 6.5 Gray administered each on a weekly
basis for a total dose of 26 Gy.
Toceranib phosphatee (2.75 mg/kg PO, 3 times
weekly) was administered. Analgesia (tramadol, parac-
etamol-codeine and firocoxib PO) combined with
monthly infusions of pamidronate were continued
throughout the treatment period. Serial clinical exami-
nations demonstrated a marked improvement of the
dog’s clinical signs and quality of life.
A repeat CT study 4 months later demonstrated mild
increase in size of the presenting lesions and progression
of the lesion in T8 to pathologic fracture. Medical treat-
ment was switched to carboplatinf (300 mg/m2 IV, every
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Fig 3. Representative images of gross, histologic and immunohistochemical features of the multicentric osteosarcoma (MOS). (A) Pho-
tomicrograph of L5 biopsy, H&E, scale bar = 100 lm. There is infiltration and replacement of pre-existing bone (star) by plump polygonal
to spindle-shaped neoplastic cells demonstrating mild to moderate nuclear atypia and formation of poor quality immature osteoid (black
arrows). (B) Photo-micrograph of L5 biopsy, positive immunoreactivity for osteocalcin antigen (brown) exhibited by the neoplastic cells
and secreted matrix, scale bar = 100 lm. (C and D) MOS in the ribs and liver respectively (white arrows). (E) Photo-micrograph of a rib
mass showing the same population as in A with more extensive osteoid production and lysis of pre-existing bone, H&E, scale
bar = 400 lm. (F) Photomicrograph of the liver mass, H&E, scale bar = 400 lm. Spindeloid neoplastic cells producing scant immature
osteoid (arrow) infiltrate the hepatic parenchyma (L).
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3–4 weeks) and after 6 cycles of treatment (9 months
after diagnosis) further imaging showed mild progres-
sive disease at existing lesions with a new pathologic
fracture at T2. Carboplatin was discontinued and the
dog was treated with chlorambucilg metronomic sched-
ule, (4 mg/m2 PO, q24 h). Three months later the dog
had pelvic limb weakness and increased pain when
going upstairs which was controlled by adding gabapen-
tin (5–10 mg/kg PO, Q8 h) to the analgesic regimen.
Upon further deterioration with lethargy and reluc-
tance to walk and increased pain, mild ataxia, paresis,
and proprioceptive pelvic limb deficits on physical
examination, a further CT scan was performed
(Fig 2B). This showed progressive disease in rib and
vertebral lesions, with stable vertebral pathological frac-
tures at T2 and T8, further vertebral collapse of T11
and impingement of spinal cord at T11 fitting with the
pain increase noted. A new lesion was observed involv-
ing the left scapula in the absence of apparent visceral
metastases. Additional analgesia with amitryptiline
(1 mg/kg PO, q12 h) and later fentanyl (3–5 lg/kg
transdermal), did not provide sustained clinical
improvement. The dog was euthanized 15 months after
diagnosis.
Postmortem examination revealed multiple lytic
lesions involving the thoracic, lumbar, and sacral verte-
bral column, pelvis, all sternebrae, ribs (Fig 3C, E), and
the left scapula. A single 1 cm diameter metastasis was
found in the right lateral liver lobe (Fig 3D, F) whereas
there were no secondary lesions in any other organs
(specifically, pulmonary involvement was not present).
A pathological fracture with mild extradural spinal cord
compression and secondary diffuse axonal degeneration
was evident at the level of T11 in association with OS
invasion. The liver and the multiple lytic bone lesions
had a similar histological appearance compared to the
previously examined surgical specimen. The numerous
slowly progressing lesions with similar histopathologic
features of OS, distributed throughout multiple axial
bones and no evidence of lung involvement confirmed
the clinical diagnosis of axial MOS.
The present report describes the clinical presentation,
diagnostic findings, treatment and long-term outcome in
an English Cocker Spaniel with axial MOS that exhib-
ited an unusual slow disease progression despite the
advanced stage at diagnosis. Multicentric osteosarcoma
is a rare presentation of OS in animals, and although
described in the horse there has yet to be a published
report of axial MOS in the dog.2 Osteosarcoma in dogs
is the most common bone neoplasia in dogs and the
appendicular presentation accounts for 75% of cases.
The axial presentation involving flat or irregular bones
is less common, with vertebral or rib location corre-
sponding only with 15 and 10%, respectively, of all
axial OS cases.3
Multicentric osteosarcoma is an uncommon clinical
presentation of OS in people; when there is a single
dominant tumor and presence of multiple skeletal sites
involved at diagnosis in the absence of visceral metasta-
sis it is called synchronous MOS, with an incidence of
0.4–4.2% within all OS cases. When additional lesions
appear at different intervals after treatment of the domi-
nant lesion, the term metasynchronous MOS is
applied.4–6 In human medicine there is a debate whether
MOS represents multiple primary tumors or metastatic
disease. In the past, the theory of multiple tumors was
favored because there was no obvious route for spread
if the lungs were free of tumor, which was thought to
rule out hematogenous dissemination. Alternatively,
the presence of cases with a large dominant lesion lead-
ing to presentation could account for the primary
tumor.5,6 Bone-to-bone metastases can occur through
intraosseous embolization through marrow sinusoids or
through the vertebral venous plexus, comprised by
valveless vessels carrying blood under low pressure,
which parallels, connects with and provides bypasses
for the portal, pulmonary and caval venous systems.
Increased intra-abdominal pressure can collapse the
vena cava and cause venous flow to be diverted into the
vertebral sinus system. This would be a similar mecha-
nism to that occurring with the distribution of prostatic
cancer bone metastases.5,7
In dogs with primary appendicular OS, additional
bone lesions at diagnosis have been considered meta-
static in nature and described to range in prevalence
from 1.4 to 28%.8–11 However, synchronous appendicu-
lar bone tumors in dogs occur without evidence of
other metastatic foci within the skeleton or lungs.12
Scarce information is available regarding prevalence of
secondary bone lesions at diagnosis in dogs with pri-
mary extracranial axial OS. The overall metastatic rate
for axial skeletal OS in dogs is 11.1%, with increased
metastatic rate of 27–38%, for rib OS compared with
other axial locations but mostly to lungs.13–15 A dog
with a primary vertebral OS of L4 and additional syn-
chronous lesions in adjacent vertebrae demonstrated
with CT was euthanized after diagnosis revealing fur-
ther lesions through L3 to L7 but also pulmonary
metastases.7
In the case described here it was impossible to deter-
mine at diagnosis if the lesions observed in multiple
bones represented synchronous/metasynchronous pri-
mary tumors, as the dog had a 1 year history of spinal
pain, or a primary vertebral OS with extensive metasta-
sis. The follow-up CT studies demonstrated slow pro-
gression of existing bone lesions and development of
only one new lesion in 14 months without pulmonary
involvement. On necropsy only one liver lesion was
identified as visceral metastasis. These findings would fit
with the description of synchronous MOS and would be
uncommon for an aggressive metastatic axial OS, that
without local control and even with systemic treatment
is usually associated with short survival times because
of rapid progression of primary and metastatic
lesions.16
Beside MOS, only few other disorders, including mul-
tiple myeloma, metastatic neoplasia, or osteomyelitis
can result in numerous lytic lesions of multiple bony
structures.17–20 Multiple myeloma was initially consid-
ered the highest differential diagnosis based on the
imaging findings. Results of diagnostic tests carried
were not suggestive for multiple myeloma and a surgical
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biopsy with subsequent histological and immuno-histo-
chemical analysis provided the final diagnosis of OS.
Immunoreactivity for vimentin antigen (mesenchymal
marker) and osteocalcin antigen (osteoblast marker)
with no immunoreactivity for MUM-1 antigen (plasma-
cytic lineage) and CD79a antigen (B-cell marker) sup-
ported the diagnosis of an OS and ruled out multiple
myeloma.21,22
A multimodal treatment approach with radical sur-
gery and cytotoxic chemotherapy provides the longest
survival times for dogs with apendicular OS.3 Local con-
trol of extracranial axial OS can be challenging. Whereas
for rib, sternebra, and scapular locations aggressive sur-
gery is possible for vertebral OS only debulking and
decompressive laminectomy are possible. Local treat-
ment failure is common in canine vertebral tumors trea-
ted with surgery or radiation plus chemotherapy or a
combination of the 3, with median survival times of
135 days.23 Because of the extensive number of lesions
in the dog presented here, treatment was aimed to con-
trol pain and improve quality of life with analgesia,
pamidronate and hypofractionated radiation treatment
to selected local lesions. Hypofractionated radiation
treatment alone or combined with chemotherapy has
been successful in controlling pain and delaying disease
progression of OS in dogs, achieving median survival
times ranging from 79 to 162 days in a variety of axial
OS.3,24,25 There is little evidence for cytotoxic
chemotherapy to improve outcome of dogs with meta-
static OS13,26–28 but stabilization of pulmonary meta-
static OS can occur with administration of tyrosine
kinase inhibitors.29 It is difficult to establish if medical
anticancer treatment in this case contributed to the long
survival by having an effect in the low rate of new
lesions or visceral metastasis development. In any case,
the survival of 15 months was longer than the expected
130 days reported for dogs with stage III OS treated
with radiation and chemotherapy.13 The continued treat-
ment with pamidronate could have also contributed to
the outcome by increasing bone density, pain control
and perhaps modulation of disease progression as docu-
mented in some case reports and given the antiprolifera-
tive effects in vitro against canine OS cells.3,30
In humans, synchronous MOS is treated with neoad-
juvant chemotherapy because of its multicentric presen-
tation, followed by wide excision of primary and
secondary bone lesions in cases with limited number of
tumoral foci and possibility of local disease control.
Response to chemotherapy assessed by quantification of
OS necrosis is associated with longer survival times.
Median time to progression with complete local control
is only around 15 months with a 5 years survival rate
of 15%.4 Prognosis differs depending on MOS type.
Type 1 affects children and adolescents, with histologic
high grade and multiple lesions involving long bones
and with an extremely poor prognosis of 6 months. In
type II, patients are usually adults and have low grade
synchronous lesions in the axial skeleton with a slightly
better prognosis of 5–72 months.4,5 On histopathology
of the case described, the tumor had mild to moderate
atypia with a good level of cell differentiation and
abundant osteoid production in different areas of the
tumor which could be classified as a low grade OS, so it
is possible that our case would be similar to the type 2
described in humans and that this would have dictated
a more benign clinical course.
In conclusion, MOS can be considered a differential
diagnosis when osteolytic lesions are present in multiple
axial bones including vertebral bodies, vertebral spinous
process, ribs, sternebrae and pelvis and laboratory
results do not support a plasma cell tumor neoplasia.
Although it is difficult to draw definitive conclusions
from the case presented here, multimodal palliative
treatment consisting of appropriate pain management,
hypofractionated radiation treatment, and anticancer
medical treatment might result in a prolonged survival
time with a good quality of life once a definitive diag-
nosis has been achieved.
Footnotes
a 1.5 tesla Intera, Philips Medical System, Eindhoven, the Nether-
lands
b 0.1 mL/kg Gadovist (gadobutrol), Bayer Pharma AG, Berlin,
Germany
c PQ 500, Universal Systems, Solon, OH
d 2 mg/kg Omnipaque (iohexol), GE Healthcare AS, Oslo,
Norway
e Toceranib, PalladiaTM, Zoetis, Louvain-la-Neuve, Belgium
f Fresenius Karbi, Bordon, United Kingdom
g Aspen, Dublin, Ireland
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